Harmony Biosciences
HRMY
44 hedge funds and large institutions have $926M invested in Harmony Biosciences in 2020 Q3 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.83% more ownership
Funds ownership: 0% → 44.83% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$330M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$165M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$137M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$128M |
| 5 |
NP
Newlight Partners
New York
|
+$97.3M |
Top Sellers
HRMY Hedge Fund Activity: Q3 2020 in Review
44 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2020, worth a combined $926M.
Buyers outnumbered sellers: 44 funds opened new HRMY positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $330M.
- 44 institutional investors held Harmony Biosciences (HRMY) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $926M of Harmony Biosciences stock for Q3 2020.
- 44 funds opened new Harmony Biosciences positions in Q3 2020 and 0 closed out, a net change of +44 holders.
- The largest Harmony Biosciences buyer in Q3 2020 was Fidelity Investments, an estimated $330M added.
Based on aggregated 13F filings for Q3 2020.